Use the hyperlinks, where available to access additional clinical trial information.
A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of BTRC4017A Administered Intravenously in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers
This trial involves a dose escalation and expansion phase. In the dose escalation phase, patients will be assigned sequentially to escalating doses of BTRC4017A, up to the maximum tolerated dose (MTD). In the dose expansion phase, patients will receive receive BTRC4017A based on the MTD or maximum allowed dose (MAD) identified during dose escalation.